Shen Meng-Yuan, Li Ze-Jiong, Wang Shu-Han, Lin Tian-Chen, Lou Qin-Yi, Liu Shan, Feng Dan-Dan, Yang Dong-Dong, Wang Chen-Juan, Ying Zhe-Kai, Zhou Rong, Wu Jian-Nong
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Zhejiang, China.
Department of Intensive Care Unit, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Front Med (Lausanne). 2025 Mar 19;12:1513272. doi: 10.3389/fmed.2025.1513272. eCollection 2025.
This study aims to conduct a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy and safety of auricular acupoint therapy (AAT) for functional gastrointestinal disorders (FGIDs).
We conducted a thorough search across eight databases, including PubMed, EMBASE, Web of Science, the Cochrane Library, CNKI, Wanfang, VIP, and CBM. The search covered the period from the inception of each database up to June 30, 2024. The authors independently reviewed all the references, evaluated the risk of bias, and extracted the data. GRADEpro software was utilized to calculate overall strength of evidence. A random effects or fixed effects model was selected on the basis of the -value and . RevMan 5.3, Stata/MP 18.0, R 4.3.1 and R Studio 2023.09.0 were used for data processing. TSA 0.9.5.10 beta software was used to evaluate data stability.
The review included 19 randomized controlled trials with a total of 1,681 patients (895 in the treatment group and 886 in the control group). The treatment duration ranged from 2-12 weeks. The meta-analysis revealed that, compared with the control, AAT was significantly more effective at treating FGIDs (RR: 1.35; 95% CI: 1.21-1.51; < 0.001), reducing the symptom score (MD: -1.94; 95% CI: -3.06 to -0.85; < 0.001; five trials), improving the SAS score (MD: -12.47; 95% CI: -13.92 to -11.01; < 0.001; five trials), and improving the SDS score (MD: -4.97; 95% CI: -9.23 to -0.72; = 0.02; six trials). A total of two articles mentioned relatively significant adverse reactions (MD: 2.98; 95% CI: 0.51-17.26; = 0.009). Sensitivity and trial sequential analyses confirmed the stability of these results.
While our meta-analysis suggests that AAT may offer benefits for FGIDs, these results must be interpreted with caution due to methodological limitations in the included trials. Further investigations in high-quality trials are warranted.
https://clinicaltrials.gov/, identifier CRD42024558786.
本研究旨在对随机对照试验进行系统评价和荟萃分析，以评估耳穴疗法（AAT）治疗功能性胃肠疾病（FGIDs）的疗效和安全性。
我们对八个数据库进行了全面检索，包括PubMed、EMBASE、Web of Science、Cochrane图书馆、中国知网（CNKI）、万方、维普（VIP）和中国生物医学文献数据库（CBM）。检索涵盖了每个数据库创建至2024年6月30日的时间段。作者独立审查了所有参考文献，评估偏倚风险，并提取数据。使用GRADEpro软件计算证据的总体强度。根据I²值和τ²值选择随机效应模型或固定效应模型。使用RevMan 5.3、Stata/MP 18.0、R 4.3.1和R Studio 2023.09.0进行数据处理。使用TSA 0.9.5.10 beta软件评估数据稳定性。
该评价纳入了19项随机对照试验，共1681例患者（治疗组895例，对照组886例）。治疗持续时间为2至12周。荟萃分析显示，与对照组相比，耳穴疗法在治疗功能性胃肠疾病方面显著更有效（RR：1.35；95%CI：1.21 - 1.51；P < 0.001），降低症状评分（MD： - 1.94；95%CI： - 3.06至 - 0.85；P < 0.001；五项试验），改善焦虑自评量表（SAS）评分（MD： - 12.47；95%CI： - 13.92至 - 11.01；P < 0.001；五项试验），以及改善抑郁自评量表（SDS）评分（MD： - 4.97；95%CI： - 9.23至 - 0.72；P = 0.02；六项试验）。共有两篇文章提到相对显著的不良反应（MD：2.98；95%CI：0.51 - 17.26；P = 0.009）。敏感性分析和试验序贯分析证实了这些结果的稳定性。
虽然我们的荟萃分析表明耳穴疗法可能对功能性胃肠疾病有益，但由于纳入试验的方法学局限性，这些结果必须谨慎解释。有必要在高质量试验中进行进一步研究。
